News | September 04, 2024
Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Dhiraj brings 20+ years of extensive executive-level financial expertise across various industries including Pharma, Media, Retail, and FMCG
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Subscribe To Our Newsletter & Stay Updated
